Qu Biologics Opens Clinical Trial Sites in Edmonton and Toronto

Home » Status Update » Qu Biologics Opens Clinical Trial Sites in Edmonton and Toronto

Vancouver, British Columbia – April 24, 2015 – Qu Biologics Inc., a biotechnology company developing Site Specific Immunomodulators (SSIs) that aim to restore the body’s normal immune function in the targeted diseased organ, announced today it has opened two new clinical trial sites in Edmonton, Alberta and Toronto, Ontario to enroll participants in its Crohn’s disease clinical trial.

Qu Biologics’ Crohn’s disease clinical trial is a randomized, placebo-controlled research trial enrolling participants living with moderate-to-severe Crohn’s disease. The trial involves the use of Qu Biologics’ QBECO SSI, a novel immunotherapy treatment derived from components of inactivated E. coli bacteria, designed to stimulate an innate immune response in the gastrointestinal tract to reverse the underlying chronic inflammation related to Crohn’s disease. The clinical trial takes place in Vancouver, Edmonton and Toronto.

Qu Biologics’ CEO Dr. Hal Gunn commented, “Opening trial sites in Edmonton and Toronto allow participants from other provinces to access our clinical trial closer to home.”  He added, “These two new clinical trial sites will also help us accelerate our goal of completing trial enrollment by Q3 2015 and obtaining primary results by the end of the year.”

For more information about the clinical trial, please visit www.qucrohnstrial.com or call 1.855.209.9680.

About Qu Biologics
Qu Biologics develops Site Specific Immunomodulators (SSI), a novel class of immunotherapies that aim to restore the body’s normal immune response. SSIs are designed to stimulate an innate immune response in targeted organs or tissues to reverse the chronic inflammation underlying many conditions including cancer and immune-related diseases such as inflammatory bowel diseases. The company is currently recruiting participants for a placebo-controlled, randomized clinical trial in Crohn’s disease and a clinical trial in non-small cell lung cancer, and plans to initiate a trial in ulcerative colitis in Q2 2015.

Backed by a prestigious group of scientific advisors and board members, Qu Biologics is led by a management team that includes co-founder and CEO Dr. Hal Gunn, a physician and expert on the body’s immune response to chronic disease, Chief Medical Officer Dr. Simon Sutcliffe, former CEO of the BC Cancer Agency and a distinguished clinician, scientist and leader in cancer control internationally, and Chief Scientific Officer Dr. David Mullins, Assistant Professor of Microbiology and Immunology in the Norris Cotton Cancer Center at the Geisel School of Medicine at Dartmouth, and recognized expert in immune cell trafficking to tumours.  For more information, visit www.qubiologics.com.

For more information regarding this press release, contact:

Julie Jang
Director, Communications
Qu Biologics Inc.
Phone:  604.734.1450 ext.41491
Email: julie@qubiologics.com

Posted on